Public Health Impact of Paxlovid as Treatment for COVID-19, United States
We evaluated the population-level benefits of expanding treatment with the antiviral drug Paxlovid (nirmatrelvir/ritonavir) in the United States for SARS-CoV-2 Omicron variant infections. Using a multiscale mathematical model, we found that treating 20% of symptomatic case-patients with Paxlovid over a period of 300 days beginning in January 2022 resulted in life and cost savings. In a low-transmission scenario (effective reproduction number of 1.2), this approach could avert 0.28 million (95% CI 0.03–0.59 million) hospitalizations and save US $56.95 billion (95% CI US $2.62–$122.63 billion). In a higher transmission scenario (effective reproduction number of 3), the benefits increase, potentially preventing 0.85 million (95% CI 0.36–1.38 million) hospitalizations and saving US $170.17 billion (95% CI US $60.49–$286.14 billion). Our findings suggest that timely and widespread use of Paxlovid could be an effective and economical approach to mitigate the effects of COVID-19..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
|---|---|
| Enthalten in: |
Emerging Infectious Diseases - 30(2024), 2, Seite 262-269 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yuan Bai [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
COVID-19 |
|---|
| doi: |
10.3201/eid3002.230835 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ096503254 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ096503254 | ||
| 003 | DE-627 | ||
| 005 | 20240413152144.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240413s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3201/eid3002.230835 |2 doi | |
| 035 | |a (DE-627)DOAJ096503254 | ||
| 035 | |a (DE-599)DOAJ4653e5e2b94b43c391f1da180f05c86f | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC109-216 | |
| 100 | 0 | |a Yuan Bai |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Public Health Impact of Paxlovid as Treatment for COVID-19, United States |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a We evaluated the population-level benefits of expanding treatment with the antiviral drug Paxlovid (nirmatrelvir/ritonavir) in the United States for SARS-CoV-2 Omicron variant infections. Using a multiscale mathematical model, we found that treating 20% of symptomatic case-patients with Paxlovid over a period of 300 days beginning in January 2022 resulted in life and cost savings. In a low-transmission scenario (effective reproduction number of 1.2), this approach could avert 0.28 million (95% CI 0.03–0.59 million) hospitalizations and save US $56.95 billion (95% CI US $2.62–$122.63 billion). In a higher transmission scenario (effective reproduction number of 3), the benefits increase, potentially preventing 0.85 million (95% CI 0.36–1.38 million) hospitalizations and saving US $170.17 billion (95% CI US $60.49–$286.14 billion). Our findings suggest that timely and widespread use of Paxlovid could be an effective and economical approach to mitigate the effects of COVID-19. | ||
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Paxlovid | |
| 650 | 4 | |a coronavirus disease | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a severe acute respiratory syndrome coronavirus 2 | |
| 650 | 4 | |a viruses | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 653 | 0 | |a Infectious and parasitic diseases | |
| 700 | 0 | |a Zhanwei Du |e verfasserin |4 aut | |
| 700 | 0 | |a Lin Wang |e verfasserin |4 aut | |
| 700 | 0 | |a Eric H.Y. Lau |e verfasserin |4 aut | |
| 700 | 0 | |a Isaac Chun-Hai Fung |e verfasserin |4 aut | |
| 700 | 0 | |a Petter Holme |e verfasserin |4 aut | |
| 700 | 0 | |a Benjamin J. Cowling |e verfasserin |4 aut | |
| 700 | 0 | |a Alison P. Galvani |e verfasserin |4 aut | |
| 700 | 0 | |a Robert M. Krug |e verfasserin |4 aut | |
| 700 | 0 | |a Lauren Ancel Meyers |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Emerging Infectious Diseases |d Centers for Disease Control and Prevention, 2003 |g 30(2024), 2, Seite 262-269 |w (DE-627)DOAJ000014966 |x 10806059 |7 nnns |
| 773 | 1 | 8 | |g volume:30 |g year:2024 |g number:2 |g pages:262-269 |
| 856 | 4 | 0 | |u https://doi.org/10.3201/eid3002.230835 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/4653e5e2b94b43c391f1da180f05c86f |z kostenfrei |
| 856 | 4 | 0 | |u https://wwwnc.cdc.gov/eid/article/30/2/23-0835_article |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1080-6040 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1080-6059 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 30 |j 2024 |e 2 |h 262-269 | ||